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ABSTRACT
We study the production of radioisotopes for nuclear medicine in (γ, γ′) photoexcitation reactions or (γ, xn+yp)
photonuclear reactions for the examples of 195mPt,117mSn and 44Ti with high flux [(1013 − 1015)γ/s], small
beam diameter and small energy band width (∆E/E ≈ 10−3 − 10−4) γ beams. In order to realize an optimum
γ-focal spot, a refractive γ-lens consisting of a stack of many concave micro-lenses will be used. It allows for
the production of a high specific activity and the use of enriched isotopes. For photonuclear reactions with a
narrow γ beam, the energy deposition in the target can be reduced by using a stack of thin target wires, hence
avoiding direct stopping of the Compton electrons and e+e− pairs. The well-defined initial excitation energy
of the compound nucleus leads to a small number of reaction channels and enables new combinations of target
isotope and final radioisotope. The narrow-bandwidth γ excitation may make use of collective resonances in
γ-width, leading to increased cross sections. (γ, γ′) isomer production via specially selected γ cascades allows
to produce high specific activity in multiple excitations, where no back-pumping of the isomer to the ground
state occurs. The produced isotopes will open the way for completely new clinical applications of radioisotopes.
For example 195mPt could be used to verify the patient’s response to chemotherapy with platinum compounds
before a complete treatment is performed. In targeted radionuclide therapy the short-range Auger and conversion
electrons of 195mPt and 117mSn enable a very local treatment. The generator 44Ti allows for a PET with an
additional γ-quantum (γ-PET), resulting in a reduced dose or better spatial resolution.
Keywords: Gamma-ray sources, Photonuclear reactions, Radioactive sources for therapy, Nuclear medicine
imaging, Radiopharmaceuticals, Gamma-ray lens
1. INTRODUCTION
This publication is intended to focus in more detail on three medical radioisotpes 195mPt, 117mSn and 44Ti, while
the more general concepts of medical radioisotope production with brilliant γ-beams have been introduced in
Ref.1 In nuclear medicine radioisotopes are used for diagnostic and therapeutic purposes.2, 3 Many diagnostics
applications are based on molecular imaging methods, i.e. either on positron emitters for 3D imaging with PET
(positron emission tomography) or gamma ray emitters for 2D imaging with planar gamma cameras or 3D imaging
with SPECT (single-photon emission computer tomography)∗. The main advantage of nuclear medicine methods
is the high sensitivity of the detection systems that allows using tracers at extremely low concentrations. This
extremely low amount of radiotracers assures that they do not show any (bio-)chemical effect on the organism.
Thus, the diagnostic procedure does not interfere with the normal body functions and provides direct information
on them, not perturbed by the detection method. To maintain these intrinsic advantages of nuclear medicine
diagnostics, one has to assure that radiotracers of relatively high specific activity are used, i.e. that the injected
radiotracer is not accompanied by too many stable isotopes of the same (or a chemically similar) element.
Radioisotopes are also used for therapeutic applications, in particular for endo-radiotherapy. Targeted sys-
temic therapies allow fighting diseases that are non-localized, e.g. leukemia and other cancer types in an advanced
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∗Today the nuclear medicine imaging techniques PET and SPECT (using radionuclides injected into the patient’s body)
are frequently combined in the same apparatus with the radiology technique CT (computer tomography) to PET/CT or
SPECT/CT, respectively
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state, when already multiple metastases have been created. Usually a bioconjugate2, 6 is used that shows a high
affinity and selectivity to bind to peptide receptors or antigens that are overexpressed on certain cancer cells
with respect to normal cells. Combining such a bioconjugate with a suitable radioisotope, such as a low-energy
electron emitter, allows irradiating and destroying selectively the cancer cells. Depending on the nature of the
bioconjugate, these therapies are called Peptide Receptor Radio Therapy (PRRT)3, 4 when peptides are used as
bioconjugates or radioimmunotherapy (RIT),3, 5 when antibodies are used as bioconjugates. The radioisotopes
for labeling of the bioconjugates should have a high specific activity to minimize injection of bioconjugates labeled
with stable isotopes that do not show radiotherapeutic efficiency. Thus again high specific activities are required
for radioisotopes used in such therapies. In the cases of 195mPt and 117mSn for radiotherapeutic applications a
low-energy γ transition can be used for SPEC imaging.
The long-lived 44Ti isotope ( T1/2 ≈ 60a) will be used as a generator to produce the shorter-lived
44Sc (T1/2=
4 h), which has the unique property to populate predominantly the first excited 1157 keV state in 44Ca. Thus the
e+ annihilation into two counterpropagating 511 keV γ-quanta is accompanied by the third prompt γ transition
of 1157 keV, allowing a unique localization of each individual decay.25 Previously already one 44Ti generator
has been produced via the 44Sc(p,2n) reaction in an irradiation for several months. All the development of the
44Ti/44Sc generator and the medical application of 44Sc to patients have been established.22, 23
The radioisotopes for diagnostic or therapeutic nuclear medicine applications are usually produced by nuclear
reactions. The required projectiles are typically either neutrons from dedicated reactors or charged particles from
cyclotrons or other accelerators. In our publication1 we have compared these methods in detail to a production
scheme using a γ-beam and discussed a large variety of new possible radioisotopes produced by γ-beams. In
section 2 we describe the most recent developments on brilliant γ-beams. In section 3 we describe a γ lens, with
which the specific activity can be increased by optimum focusing at the production target. While the γ facilities
allow to produce many radioisotopes in new photonuclear reactions with significantly higher specific activity, we
here focus on the three radioisotopes 195mPt, 117mSn and 44Ti. In section 4 we discuss these special cases.
2. HIGHLY BRILLIANT γ SOURCES
The new γ beams are produced via Compton back-scattering of laser photons from a relativistic electron beam.
The presently world-leading facility for photonuclear physics is the High-Intensity γ-ray Source (HIγS) at Duke
University (USA). It uses the Compton back-scattering of photons, provided by a high-intensity Free-Electron
Laser (FEL), in order to produce a brilliant γ beam. The γ intensity in the energy range between 1MeV
and 160MeV amounts to 108s−1 with a band width of about 5%.11 The brilliant Mono-Energetic Gamma-
ray (MEGa-ray) facility at Lawrence Livermore National Laboratory (USA) is based on a normal-conducting
electron linac and will yield already in 2012 for γ energies between 0.5 and 2.5 MeV a γ intensity of 1013s−1
with an energy band width of down to 10−3 and a brilliance of 1022/[mm2mrad2s0.1%BW ].12 Using the same
accelerator technology, at the upcoming Extreme Light Infrastructure - Nuclear Physics (ELI-NP) facility in
Bucharest, until 2015 a γ beam will become available, providing about the same γ intensity and band width in
the energy range of 1-19MeV.13
At present, great efforts are also invested all over the world to realize highly brilliant γ beams based on the Energy
Recovery Linac (ERL) technology. The Energy Recovery Linac (ERL) requires a new type of superconducting
electron accelerator that provides a highly brilliant, high-intensity electron beam. The main components of
an ERL are an electron injector, a superconducting linac, and an energy recovery loop. After injection from
a highly brilliant electron source, the electrons are accelerated by the time-varying radio-frequency field of the
superconducting linac. The electron bunches are transported once through a recirculation loop and are re-injected
into the linac during the decelerating RF phase of the superconducting cavities. So the beam dump has to take
the electron bunches only with low energy, while the main part of the electron energy is recycled. At ERL’s,
high-energy, highly brilliant γ beams can be created by Compton back-scattering of photons with high energy
(0.1-100MeV), again recirculating the photons in a very high finesse cavity with MW power to overcome the
small Compton cross section. ERL technology is pioneered at Cornell University (together with Thomas Jefferson
National Laboratory),16–18 where an ERL is presently constructed for a 5GeV, 100 mA electron beam. At the
KEK accelerator facility in Japan, an ERL project is presently pursued aiming at a γ beam with an intensity
of 1013s−1.14, 15 In Germany, a high-current and low-emittance demonstrator ERL facility (BERLinPro) is
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Figure 1. γ-lens consisting of N micro-lenses, irradiated with a γ-beam of radius R. The γ lens has a focal length f .
developed at the Helmholtz Zentrum Berlin.19 There are mainly three different operation modes of an ERL:
high-flux mode, high-brilliance mode, and a short-pulse mode.15–17 For our purpose of medical isotope production
the high brilliance mode is of particular interest. The ultimately envisaged photon intensity is > 1015s−1 in an
energy range of 0.5 - 25MeV. Such a facility would provide a brilliant pulsed (ps pulse length) γ beam with a
narrow band width of about < 10−3, and a low emittance of 10−4mm2mrad2.
3. γ LENS WITH MONOCHROMATISATION
Lenses for hard X-rays are well established7–10 for energies up to 200 keV. At synchrotrons the brilliance decreases
more than exponential above 100 keV energies. Here we want to extend the range of these lenses to MeV-γ-
beams, making use of their many orders of magnitude higher brilliance. Since the real part δ of the index of
refraction n = 1−δ+iβ decreases with 1/E2γ , the realization of sufficent focusing strength becomes more difficult.
On the other hand, the imaginary part β of the index of refraction decreases even faster with 1/E3.5γ . At higher
energies new processes like Compton scattering and pair creation contribute to β. Only with the new highly
brilliant γ-beams the smaller beam radius R allows to reach reasonable focal lengths f . A further trick to reduce
the focal length is to stack a larger number N of micro-lenses behind each other. The focal length f is given by
f =
R
2δN
(1)
For the real part δ of the index of refraction we have:
δ =
reλ
2
γ
2pi
ρ
Z
A
∝
1
E2γ
(2)
Here re is the classical electron radius, λγ =
h¯c
Eγ
is the γ wavelength, ρ is the lens density and Z and A are
the charge and mass number of the lens material, respectively. Since the real part δ of the index of refraction is
negative for γ-energies, we show concave lenses in Fig. 1.
We now have to consider the special case that we will use in combination with the γ-lens always γ-beams
produced by Compton back-scattering from relativistic electrons. Here the γ-energy Eγ is given by:
Eγ =
2γ2e · (1 + cosφ) · EL
1 + (γeΘ)2 +
4γeEL
mec2
(3)
EL is energy of the primary laser photons, γe =
Ee
mec2
is the γ-factor of the electron beam with energy Ee
and the electron rest mass me and we consider that the laser beam enters under an angle φ with respect to the
electron direction and the outcoming γ photon has an angle Θ with respect to the electron beam direction. Thus
for Θ = 1/γe the emitted γ photon has about a factor of 2 smaller γ-energy that the γ-photon in electron beam
direction. For angles ΘBW ≤
√
BW
γe
, the central γ beam opening cone, it is no longer the Θ dependance of the
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Compton scattering, but other factors like the band width of the electron beam or the band width of the laser
beam, which determine the band width BW of the γ-beam. We will now limit the acceptance angle of the γ
lens or the corresponding γ beam radius R at the entrace to the lens to this much smaller angle ΘBW , where
furthermore the main intensity of the γ beam is concentrated. Thus we make use of the very special γ energy
angle correlation of Compton backscattered γ rays to work with a very small radius R and to obtain a natural
monochromatisation. The outer angles Θ are no longer focused by the lens. We can experimentally monitor
the energy range focused by the lens by using a special nuclear resonance γ energy and measure the nuclear
resonance fluorescence (NRF) for a thin wire target, probing the γ beam focus behind the γ lens. The better
the band width of the central γ beam the smaller the radius R and the focal length f will be. For higher γ
beam energies and correspondingly larger γe the radius R will be smaller, partially compensating the strong γ
energy dependance of the focal length f with ∝ 1E2γ
∝ 1γ4e
. By increasing the number N of micro-lenses and using
materials of higher density ρ, we can keep the focal length sufficiently small for γ beams with sufficiently good
primary band width BW. In the very central region the very thin micro-lenses will lead to small absortion of the
γ beam. We have to align the γ lens very accurately with respect to the electron beam direction, but again this
can be monitored by NRF measurements.
When reducing the γ beam radius along the stack of lenses, the shape of the lenses can be adjusted adiabati-
cally and very small focal spots can be reached.7 For our production of medical radioisotopes we want to reach a
very small spot size on the target to obtain higher specific activity and to allow for the use of isotopically enriched
targets. The small diameter wire-targets allow for an easy escape of Compton electrons and pairs, resulting in
little heating.
4. SPECIAL RADIOISOTOPES
4.1 The nuclei 195Pt and 117Sn
195Pt and 117,119Sn have many common properties. 195Pt has above its 1/2−[530] Nilsson ground state a
13/2+[606] isomer at 259 keV with a halflife of 4 d. The isomer originates from the 1i13/2 intruder state
from the next higher shell. For the semi-magic 117,119Sn with Z=50, the situation is very similar to 195Pt, except
that all angular momenta and the main shell quantum number are reduced by one. Thus the intruder 1i13/2 state
of 195Pt is replaced by the intruder 1h11/2 state for
117Sn. The ground state 1/2+[404] of 117,119Sn originates
from a 2d3/2 state. The 11/2
− isomer at 315 keV of 117Sn originates from the 1h11/2 neutron state and has a
half-life of T1/2= 13.6 d. The corresponding 11/2
− isomer of 119Sn at 89.5 keV has a half-life of T1/2=293 d,
which is too long for medical applications.
But also the neighbouring even-even nuclei have many similarities. The Pt nuclei have close-lying shell model
states with ∆N = 1,∆l = ∆j = 3,20, 21 here the i13/2 and f7/2 states, which lead to octupole deformation
and low-lying collective 3− states. These 3− octupole states are coupled to 2+ quadrupole states, resulting in
collective 1− states. One could also couple a collective 5− and 4+ to a collective 1− state. These 1− states
have rather large dipole moments of about 0.1 e fm. The 5− state may be due to shell model states with an
angular momentum difference ∆l = ∆j = 5 of the i13/2 and p3/2 states. In this way one could explain the strong
E1 core excitation and its strong collective core deexcitation by a 1− → 3− → 5− cascade with collective E2
transitions. The 5− core excitation then will decay predominantly to the i+
13/2 state. The f and p shell-model
states lying close to the i shell-model state explain the collective 3−, 5− core excitations in the neighbouring
194,196Pt isotopes. Also on top of the 13/2− isomer low-lying collective quadrupole excitations exist, which will
mix with the high-spin states of the core 3− and 5− excitations and the 1/2+ ground state, leading to the strong
cascade coupling the gateway state with the 1− core excitation to the high spin isomer.
Also for the Sn nuclei we have close-lying shell-model states with ∆N = 1,∆l = ∆J = 3 to explain the strong
octupole state and by coupling to the 2+ quadrupole state the dipole E1 transition.21
We can extrapolate all these collective states of neighbouring even-even nuclei to the odd-neutron 195Pt and
117Sn. We verify a weak coupling of the core excitations for known collective states in these odd nuclei. Thus we
predict a 1/2+ and 3/2+ E1 excitation from the 1/2− ground state to the 1− core excitation at about 1.8 MeV
for 195Pt and a 1/2− and 3/2− E1 core excitation from the ground state of 117Sn at about 3.8 MeV.
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Figure 2. Statistical model calculation for the cross section with the TALYS code, giving the broad cross-section
dependence and predicted additional collective resonances deduced from neighbouring even-even nuclei.
4.1.1 Production of the Isomers 195mPt and 117mSn
In Fig. 2 we show the predicted photonuclear cross-sections as a function of γ-energy. Besides the statistical
calculations with the TALYS code and standard parameters, we show the new expected collective gateway states.
Their relative yield has to be adjusted to reproduce the integrated yields. At present for 195Pt and 117Sn only
one survey experiment including 19 nuclides exists, where the integrated cross section σ · Γ was deduced for
one bremsstrahlung spectrum ranging from 0.5 MeV to 4 MeV and another one ranging from 1.0 MeV to 6
MeV. A “three to four orders of magnitude larger integrated cross section than usually” was observed including
195mPt and 117mSn.28 In the analysis one single gateway state at 2.125 MeV was artificially introduced for all
19 nuclides, when deducing the effective σ · Γ. We now want to perform at HIγS a search for these individual
resonant gateway states for 195Pt and 117Sn. Then we could localize them more accurately with the better band
width of the MEGa-ray or ELI-NP facilities. These resonances would facilitate the photonuclear production of
these isomers significantly.
4.1.2 Medical Applications of 195mPt and 117mSn
195mPt: Determining the efficiency of chemotherapy for tumors and the optimum dose by nuclear
imaging In chemotherapy of tumors most often platinum cytotoxic compounds like cisplatin or carbonplatin are
used. We want to label these compounds with 195mPt for pharmacokinetic studies like tumor uptake and want to
exclude “nonresponding” patients from unnecessary chemotherapy and optimizing the dose of all chemotherapy.
For such a diagnostics a large-scale market can be foreseen, but it would also save many people from painful
treatments. We estimated in Ref.1 that several hundred patient-specific uptake samples per day could be
produced with a γ beam facility if optimum gateway states are identified by scanning the isomer production
with high γ beam resolution. 195mPt has a high 13/2+ spin isomer at 259 keV, halflife (T1/2= 4 d) with SPECT
transitions of 130 keV and 99 keV to the 1/2− ground state.
195mPt: Cancer Therapy with Short-Range Electrons On the other hand, 195mPt may be used in
cancer therapy by transporting it to the tumor by specific bioconjugates.29 Special antibodies may be used in
radio-imunotherapy (RIT) or special peptides in Peptide Receptor Radionuclide therapy (PRRT) to guide the
radioactive isotope to the tumor. In Fig. 3 we show how a radionuclide like 195mPt is transported with a chelator
to the specific peptide receptor.
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Figure 3. Schematic picture explaining how a specific radionuclide can be transported to a specific petide receptor.
Here 195mPt is of high interest, because the emitted conversion electrons and Auger electrons have a rather
small range of 1.5-200 µm and low electron energies of 7 keV, 17 keV, 21 keV and 116 keV, respectively. They
allow to kill locally small tumor clusters, while the dose given to normal tissue is rather low. Several new
therapeutic radioisotopes with this small range and high LET can be produced by γ beams.
117mSn An emitter of low energy Auger electrons for tumor therapy Auger electron therapy requires
targeting into individual tumor cells, even into the nucleus or to DNA, due to the short range below 1µm of the
Auger electrons; but there it is of high REB due to the shower of the abundantly produced 5-30 Auger electrons.32
On the other hand, Auger radiation is of low toxicity, while being transported through the body. Thus Auger
electron therapy30 needs special tumor-specific transport molecules like antibodies or peptides. Many of the
low-lying high spin isomers produced in (γ, γ′) reactions have strongly converted transitions, which trigger these
large showers of Auger cascades.
Once the optimum production of the isomers 195mPt and 117mSn has been established, the scientific focus
will shift to produce the best bioconjugates to transport these radioisotopes to specific cancer cells.
4.2 The Generator 44Ti
4.2.1 Photoproduction of 44Ti
In the α-cluster model, 46Ti and 44Ti have a simple structure. Both nuclei have a strongly bound doubly magic
40Ca core, which in the α-cluster model consists of 10 α particles forming the spherical core. For 44Ti we add
an additional α particle to the doubly magic 40Ca core, obtaining a deformed nucleus. 46Ti can be obtained by
adding two valence neutrons to the 44Ti. This structure is shown in Fig. 4.
The very strongly bound α particles make it probable that we obtain two loosely bound halo neutrons when
we photo-excite 46Ti, such that it can emit just two low-energy neutrons. Since these halo neutrons result in
large dipole monents and strong E1 excitations, we expect strong collective resonances close to the reaction
threshold. We expect a deformation splitting with a deformation of 46Ti of about β = 0.3, resulting in a high-
energy component EGDR⊥ = EGDR · (1 + β/3), corresponding to about 24.1 MeV, and a low-energy component
EGDRz = EGDR ·(1−β ·(2/3)), corresponding to about 17.5 MeV. This GDR is shown in Fig. 5 with its splitting
due to the quadrupole deformation into a high-energy component EGDR⊥ with an oscillation normal to the z
Ca40
α’s10
valence
neutrons
α
Figure 4. α-cluster model of 46Ti.
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Figure 5. Schematic E1 strength of 46Ti. The γ width of about 1.3 eV at 13.2 MeV is confirmed in Ref.33
axis, and a component half as strong at EGDRz along the z axis. Microscopically, in the E1 excitation we have
to lift up two 1f7/2 neutrons to form 1− states. Thus we will have 3s1/2 neutron levels populated close to zero
binding energy, but also some odd angular momentum states. These weakly bound states will decay sequencially
into two neutrons above the 2n-threshold, but due to the s-neutron components in the wavefunctions they will
have extended wave functions and an enhanced E1 strength.
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Figure 6. Cross section for the 46Ti(γ, 2n)44Ti reaction calculated with the TALYS code. Also shown is a halo resonance
at the reaction threshold.
In Fig. 6 we show in red the usual energy dependence of the 46Ti(γ,2n)44Ti cross section from statistical
model simulations with the code TALYS. In addition we hope to find this predicted strong new resonance.
4.2.2 A 44T i→44Sc generator for the γ-PET isotope
In recent years PET (Positron Emission Tomography) with a typical spatial resolution of 3-10 mm was sup-
plemented by multi-slice X-ray CT (Computer Tomography) of much better resolution, leading to the novel
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Figure 7. Schematic picture for the combined γ-PET and the 44Ti/44Sc generator.
technology of PET/CT. The co-registration and the reference frame of CT are very helpful for the interpretation
of PET images. CT and PET require a comparable dose. Looking at such images it is very apparent, that a
significant improvement in the resolution of PET is highly desirable. 44Sc is the best candidate to supply the two
511 keV annihilation quanta together with a strongly populated 1.157 MeV transition as shown in Fig. 7. By
measuring the position and direction of this γ-ray accurately with a Compton spectrometer together with the two
511 keV quanta, the location of the emitting nucleus can be located in 3 dimensions. In conventional PET the
two collinear 511 keV quanta only allow to determine a two-dimensional localization on a line of response. Thus
a much better spatial resolution can be achieved for the same dose with γ-PET compared to PET. With 44Ti
(half-life T1/2= 59 a), the production with a very promising generator for
44Sc (T1/2= 3.9 h) becomes available
with γ beams. Again a much stronger population via the fine structure of the Giant Dipole Resonance (GDR) in
the 46Ti(γ,2n)44Ti reaction is expected for the 44Ti core consisting of the doubly magic 40Ca and an α particle.
The long halflife of 44Ti requires a large transmutation with an intense γ beam, but on the other hand leads
to a very valuable, long-lived generator. The production of 44Ti in the (γ,2n) reaction requires rather large γ
energies of 21-24 MeV, and would require an increase of the maximum presently planned γ energy at ELI-NP of
19 MeV. This seems possible, since an increase of the electron beam energy by 10% should be achievable after
some experience with the accelerator cavities.
4.2.3 γ-PET
The Medium Energy Gamma-ray Astronomy library (MEGAlib)27 contains all software tools to perform simula-
tions for Compton cameras.24, 26 Similar to measurements in PET detectors, we are including here the detector
positions of the coincident 511 keV γ-rays emitted back-to-back in order to determine their common direction.
Then we combine this direction of the two 511 keV quanta with the direction of the Compton cone of the 1157
keV quantum. Here are to possiblities of a Compton camera. In the first method we only measure the energy of
the Compton scattered electron in the detector together with the direction and energy of the scattered γ ray and
obtain by energy considerations the Compton cone as possible directions of the primary γ ray. In a more refind
measurement we can measure the momentum of the Compton electron, we measure also its direction. Then we
can limit the direction of the primary γ photon to a small section of the Compton cone. We reach accuracies for
the primary γ ray of about 10. In this way we can filter out on an event-by-event basis the good events, where
the reconstruction of the 3D decay location is restricted very much. For the lower energy 511 keV quanta we
probably only can reconstruct their Compton cones to determine some Compton scattering in the patient, while
for the 1257 keV γ photons we can measure the Compton electron momentum. This reconstruction of the source
is very different from the usual PET reconstruction, where the lines of different annihilation decays are combined
to reconstruct the source position. If one or more of the three γ quanta (511 keV, 511 keV, 1157 keV) undergo
a Compton scattering in the patient, they are strongly suppressed by the analysis including the algorithmus of
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the Compton camera, reducing the blurring of the usual PET-analysis by this Compton scattering within the
patient strongly. While the diffusion of the positron with a maximum energy of 2 MeV results in a deviation
in the annihilation position from the original 44Sc decay, the prompt 1157 keV photon originates from the 44Sc
decay. In detailed simulations we want to determine in how far the γ-PET technique results in a strong dose
reduction and improved spatial resolution compared to the classical PET analysis.
This γ-PET imaging techniques can be tested with a 22Na source, where the β+ decay again leads predomi-
nantly (in about 90%) to the 2+-level of 22Ne at 1274.6 keV. However, the long lifetime of 22Na of 2.6 a allows
no use in medicine.
5. CONCLUSION
Many further new interesting medical radioisotpes can be produced (see Ref.1): new ’matched pairs’ of isotopes
of the same element become available, one for diagnostics, the other for therapy, allowing to contol and optimize
the transport of the isotope by a bioconjugate to the tumor. Also new therapy isotopes become available like
225Ac, where four consecutive α decays can cause much more DNA double-strand breaking. Developing these
techniques and applications is a promising task of ELI-NP with a strong societal component.
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